过去一年中添加的文章，按日期排序
[HTML][HTML] Profile of Dermatologic Side Effects of Tyrosine Kinase Inhibitor (EGFR-TKIs) in Lung Cancer Patients
E Napitupulu, A Nurrochmad, AR Hanafi… - … FARMASI (Journal of … - journal.ugm.ac.id
17 天前 - … Objectives: This study aims to provide an … : This study used a cross-sectional design.
Inclusion criteria were patients who received EGFR-TKIs targeted therapy, namely gefitinib, …
Inclusion criteria were patients who received EGFR-TKIs targeted therapy, namely gefitinib, …
The elusive search for the ideal pharmacological treatment for Cushing disease
M Mercado - Endocrinology, 2024 - academic.oup.com
32 天前 - … tyrosine kinase inhibitors targeting the epidermal growth factor receptor like gefitinib
or … and cyclin E, which is currently being evaluated in humans in a phase II clinical trial (…
or … and cyclin E, which is currently being evaluated in humans in a phase II clinical trial (…
Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with …
M Hachlaf, S Lkhoyaali, W Nadir, H Lemsyeh… - Journal of Medical Case …, 2024 - Springer
44 天前 - … -epithelial growth factor receptor tyrosine kinase inhibitors … adenocarcinoma with
epithelial growth factor receptor mutations, … The OCEAN study is a prospective phase II trial that …
epithelial growth factor receptor mutations, … The OCEAN study is a prospective phase II trial that …
Investigation of Egfr Inhibition Potential of Some Natural Compounds from Ganoderma Amboinense Using Dft, Molecular Docking, Molecular Dynamics Simulations …
T Erdogan, F Oguz Erdogan - Investigation of Egfr Inhibition Potential of … - papers.ssrn.com
67 天前 - … strategy is epidermal growth factor receptor tyrosine kinase (EGFR TK) inhibition.
There … were compared with those of the reference drug Gefitinib. It was observed that four of …
There … were compared with those of the reference drug Gefitinib. It was observed that four of …
[HTML][HTML] Nanoenabled intracellular zinc bursting for efficacious reversal of gefitinib resistance in lung cancer
J Li, YG Assaraf, W Zuo, Z Lin, KW Leong… - … Journal of Biological …, 2024 - ncbi.nlm.nih.gov
113 天前 - … epidermal growth factor receptor (EGFR)-activating mutations, gefitinib, one of the
first-generation tyrosine kinase … In this respect, various EGFR tyrosine kinase inhibitors (TKIs) …
first-generation tyrosine kinase … In this respect, various EGFR tyrosine kinase inhibitors (TKIs) …
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
T Landre, JB Assié, K Chouahnia… - Expert Review of …, 2024 - Taylor & Francis
113 天前 - … a mutation in the epidermal growth-factor–receptor (EGFR)… (range) durations of
gefitinib administration in the NEJ009 … -2 study were 24 (20.9–27.8) vs. 15.3 (12.7–19.4) months. …
gefitinib administration in the NEJ009 … -2 study were 24 (20.9–27.8) vs. 15.3 (12.7–19.4) months. …
Comparative analysis of the clinical efficacies of furmonertinib and gefitinib in the treatment of advanced EGFR-mutated non-small cell lung cancer
F Chengtao, Y Fang - International Medicine and Health Guidance News, 2024 - imhgn.com
204 天前 - … and gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) sensitive mutations. Methods This study was a …
with epidermal growth factor receptor (EGFR) sensitive mutations. Methods This study was a …
Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
H Darré, P Masson, A Nativel, L Villain, D Lefaudeux… - Biomedicines, 2024 - mdpi.com
221 天前 - … While tyrosine kinase inhibitors (TKIs) like gefitinib and osimertinib target this
mutation, … ) [2]. Driver mutations, like the mutation of the epidermal growth factor receptor (EGFR) …
mutation, … ) [2]. Driver mutations, like the mutation of the epidermal growth factor receptor (EGFR) …
[HTML][HTML] Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation
C Ma, X Zhang, X Mo, Y Yu, Z Xiao, J Wu, L Ding, C Lei… - Phytomedicine, 2024 - Elsevier
255 天前 - … and develop resistance to epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs), which reduce treatment efficacies. Currently, most … tyrosine kinase inhibitors …
(EGFR-TKIs), which reduce treatment efficacies. Currently, most … tyrosine kinase inhibitors …
[HTML][HTML] Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight …
A Singh, V Patil, N Menon, S More, S Jain… - Cancer Research …, 2024 - journals.lww.com
264 天前 - … , such as gefitinib, had received approval based on two studies, … Epidermal growth
factor receptor-mutated non-small-cell … The phase II Iressa dose evaluation in advanced lung …
factor receptor-mutated non-small-cell … The phase II Iressa dose evaluation in advanced lung …